Commenting on the results, Chairman and Managing Director Kiran Mazumdar-Shaw said, ?Biocon has started this financial year on a very strong note. Our group profits have grown by 33% YoY to Rs 77 crores whilst our revenues have also delivered an impressive 33% YoY growth. We have identified Biosimilars, Immunosuppressants, Research Services and the Emerging Markets as key growth drivers for the near term. We believe these will deliver sustainable shareholder value over the coming years.?

Performance Highlights

For quarter ended June 30, 2010

? Total Income at Rs 672 crores. Up 33% YoY.

? EBITDA at Rs 141 crores. YoY growth was 27%.

? PAT at Rs 77 crores. YoY growth was 33%.

? Operating Margin at 21%.

? Earnings Per Share at Rs 3.84.

? Headcount at 4,750 employees.

Business Performance and Outlook

Biopharmaceuticals

The Biopharma business posted a 37% YoY increase in revenues in the first quarter of this fiscal demonstrating excellent growth in our core businesses that include Insulins, Immunosuppressants, Statins and Branded Formulations.

Insulins ? Biocon has made significant progress in developing biosimilars for several ROW markets. Our Insulin biosimilar drug has received approval to initiate Phase III clinical trials in Europe and we expect to start recruiting patients in Q2 FY11.

Immunosuppressants ? Biocon expects significant contribution from this segment in this fiscal from several new registrations for MMF and Tacrolimus. We also expect to commercialize additional products in this segment later this year.

Statins ? The Statins segment continues to be a strong component of the business. Biocon started a capacity optimization and expansion program last year which has begun to show results, particularly in our Hyderabad facility which began operations in this quarter.

Domestic Branded Formulations ? The existing verticals in branded formulations (Diabetology, Oncotherapeutics, Nephrology and Cardiology) have posted a combined strong YoY growth of 28%. The Company will launch two new divisions in Q2 FY11 – Comprehensive Care and Immunotherapy. These new divisions will target physicians and specialists in hospitals and intensive care settings. In Q2 FY11, Biocon?s Nephrology division will launch Advacan, a drug for renal & heart transplant recipients. In the Cardiology segment, Clotide (Eptifibatide) and Myokinase (Streptokinase) maintain their No 1 and No 2 rankings in their respective categories.

Axicorp ? Our German subsidiary Axicorp has posted strong results in this quarter with a 37% YoY growth in sales.

Research Services

Syngene and Clinigene grew to a combined sales of Rs 72 crores in Q1 FY11. Operating profits were, however, impacted by higher costs associated with integrated drug development programs that are expected to yield results in the coming quarters.

Research Pipeline

Our novel pipeline has achieved significant milestones including initiation of a Phase 1 study in Type 1 diabetics for our IN-105 program, under a US IND. Our novel Anti-CD6 targeting monoclonal antibody (T1h) program has started Phase III clinical trials for Psoriasis with the first set of patients being recruited and dosed.

Corporate Developments in Q1 FY11

Biocon signs long-term supply pact with US-based Optimer Pharmaceuticals

Biocon Ltd. signed a long-term agreement with US biopharma company Optimer Pharmaceuticals Inc. for the commercial manufacturing of active pharma ingredient OPT 80. The drug is among a new class of macrocyclic antibiotics and is being developed by Optimer to treat serious colon infections such as Clostridium difficile infection and is expected to be commercialized soon. For the last five years, Biocon has been an important partner in Optimer’s Opt 80 development program and will continue this relationship with the manufacturing and supply of this product once approved.